Status:
COMPLETED
Hydrogen Gas for Cancer Rehabilitation
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborating Sponsors:
Shanghai Asclepius Meditech Co., Ltd
Conditions:
Adult Solid Tumor
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
The aim of this study is the efficacy of hydrogen gas immunotherapy to rehabilitation and prognosis of cancer patients.
Detailed Description
By enrolling patients of multiple kinds of cancer adapted to enrolled criteria, this study will document for the first time the short and long term efficacy of hydrogen gas.The evaluation indexes incl...
Eligibility Criteria
Inclusion
- Standard therapies have finished according to NCCN guidelines or the patient refuses standard therapies
- Body tumor 1-6, the maximum tumor length \< 2 cm
- KPS ≥ 70, lifespan \> 6 months
- Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Key Trial Info
Start Date :
June 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03818347
Start Date
June 2 2018
End Date
August 20 2020
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Fuda cancer institute
Guangzhou, Guangdong, China, 510665